Connor, Clark & Lunn Investment Management Ltd. Keros Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 29,146 shares of KROS stock, worth $307,781. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,146Holding current value
$307,781% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding KROS
# of Institutions
176Shares Held
31.1MCall Options Held
646KPut Options Held
670K-
Black Rock Inc. New York, NY2.51MShares$26.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.96MShares$20.7 Million0.0% of portfolio
-
Braidwell LP Stamford, CT1.89MShares$20 Million1.68% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.69MShares$17.8 Million2.53% of portfolio
-
State Street Corp Boston, MA1.2MShares$12.7 Million0.0% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $272M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...